Loading content…
Drug family · 1 brand
Dulaglutide family — Trulicity
GLP-1 receptor agonist (Fc-fusion). FDA-approved since 2014. Trial weight loss range: ~5-6% (off-label weight loss observation; not FDA-approved for obesity).
Quick answer
dulaglutide is a GLP-1 receptor agonist (Fc-fusion). FDA-approved brand-name medications containing dulaglutide: Trulicity. Trial weight loss varies from ~5-6% (off-label weight loss observation; not FDA-approved for obesity). Each brand is FDA-approved for a specific indication; prescribers choose based on patient diagnosis and insurance coverage.
- Manufacturer: Eli Lilly
- FDA indications: Type 2 diabetes + cardiovascular risk reduction (REWIND)
- Trial weight loss: ~6%
- Not FDA-approved for obesity treatment
- Frequency: Once-weekly subcutaneous injection
- Distinguishing feature: Easiest auto-injector design in class
- Pre-attached needle, single-button activation
Mechanism of action
Dulaglutide is a GLP-1 analog fused to a human IgG4 Fc fragment, dramatically extending half-life to ~5 days and enabling weekly subcutaneous dosing. The Fc-fusion construction also reduces immunogenicity. FDA-approved for type 2 diabetes glycemic control plus cardiovascular event reduction (REWIND trial, Lancet 2019). Known for simplest auto-injector device in class.
FDA-approved brands containing dulaglutide
All brands share active ingredient dulaglutide but differ in indication, dosing, and formulation.
Alternatives outside the dulaglutide family
If dulaglutide options don't fit, these GLP-1 medications use a different active ingredient:
Common questions
Why is Trulicity weight loss less than other GLP-1s?
Trulicity's Fc-fusion structure provides excellent diabetes glycemic control but produces less appetite suppression and weight loss than semaglutide or tirzepatide. Dulaglutide molecular size may limit central nervous system penetration affecting appetite regulation. Trulicity is not FDA-approved for obesity; weight loss is secondary effect in diabetes treatment.
Can I use Trulicity for weight loss?
Trulicity is FDA-approved only for type 2 diabetes. Off-label prescription for weight loss alone is uncommon since Wegovy and Zepbound are specifically FDA-approved for obesity with higher efficacy. Trulicity may produce modest weight loss as a secondary benefit during diabetes treatment.
References
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide in Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes in T2D (Marso et al., NEJM)(2016)
SELECT trial: Semaglutide for Cardiovascular Event Reduction in Obesity without Diabetes(2023)
REWIND trial: Dulaglutide and Cardiovascular Outcomes (Gerstein et al., Lancet)(2019)
AHA Scientific Statement on Obesity and Cardiovascular Disease(2021)
FLOW trial: Effects of Semaglutide on Kidney Outcomes in T2D and CKD (NEJM)(2024)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms and Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)